Introduction: Ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, is authorized for the treatment of chronic lymphocytic leukemia (CLL). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.